We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
+13.1%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$377M
AUM Growth
+$1.24M
Cap. Flow
-$2.89M
Cap. Flow %
-0.77%
Top 10 Hldgs %
89.68%
Holding
27
New
4
Increased
7
Reduced
9
Closed
3
Avg Time Held Equity + Options
8 quarters
Top 10 Avg Time Held Equity + Options
5 quarters
Top 20 Avg Time Held Equity + Options
7.3 quarters
Avg Time Held Equity only
8.3 quarters
Top 10 Avg Time Held Equity only
5 quarters
Top 20 Avg Time Held Equity only
7.3 quarters

Top Buys

Rank Stock Value
1
TSVT icon
2seventy bio
TSVT
+$5.97M
2
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$3.22M
3
SYRS icon
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$2.98M
4
KROS icon
Keros Therapeutics
KROS
+$2.32M
5
RPTX icon
Repare Therapeutics
RPTX
+$2.27M

Top Sells

Rank Stock Value
1
KZR icon
Kezar Life Sciences
KZR
+$6.94M
2
PLRX icon
Pliant Therapeutics
PLRX
+$4.78M
3
LRMR icon
Larimar Therapeutics
LRMR
+$3.8M
4
INZY icon
Inozyme Pharma
INZY
+$2.28M
5
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$1.96M

Sector Composition

Rank Sector Weight
1 Healthcare 99.97%
2 Miscellaneous 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$100M 26.61%
934,135
+10,335
+1% +$1.19M
2021 Q1
8 quarters
PLRX icon
2
Pliant Therapeutics
PLRX
$61.7M
$79.8M 21.2%
3,001,835
-168,057
-5% -$4.78M
2020 Q2
11 quarters
VECT
3
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$44.7M 11.87%
5,255,484
-237,409
-4% -$1.96M
2021 Q2
7 quarters
CGEM icon
4
Cullinan Oncology
CGEM
$961M
$34.3M 9.1%
3,349,460
+31,916
+1% +$352K
2021 Q1
8 quarters
RPTX icon
5
DELISTED
Repare Therapeutics
RPTX
$29.5M 7.83%
2,997,939
+197,813
+7% +$2.27M
2020 Q2
11 quarters
LRMR icon
6
Larimar Therapeutics
LRMR
$268M
$12.4M 3.3%
2,746,265
-727,101
-21% -$3.8M
2020 Q2
11 quarters
KROS icon
7
Keros Therapeutics
KROS
$232M
$11.1M 2.96%
261,059
+46,000
+21% +$2.32M
2020 Q2
11 quarters
CMPX icon
8
Compass Therapeutics
CMPX
$167M
$9.25M 2.46%
2,829,712
– –
2021 Q4
5 quarters
TSVT icon
9
DELISTED
2seventy bio
TSVT
$8.72M 2.32%
855,000
+521,748
+157% +$5.97M
2022 Q1
4 quarters
INZY icon
10
DELISTED
Inozyme Pharma
INZY
$7.69M 2.04%
1,342,191
-862,685
-39% -$2.28M
2020 Q3
10 quarters
OMGA icon
11
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$6.37M 1.69%
1,055,882
– –
2021 Q3
6 quarters
IMA icon
12
ImageneBio Inc
IMA
$48.2M
$5.73M 1.52%
138,406
+1,958
+1% +$90K
2021 Q1
8 quarters
RLYB icon
13
Rallybio
RLYB
$89.9M
$4.34M 1.15%
95,068
+4,304
+5% +$222K
2022 Q3
2 quarters
ORTX
14
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$4.22M 1.12%
785,738
-13,002
-2% -$70.7K
2019 Q3
14 quarters
KDNY
15
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$3.13M 0.83%
+135,000
New +$3.22M
2023 Q1
0 quarters
DTIL icon
16
Precision BioSciences
DTIL
$180M
$2.61M 0.69%
115,661
-2,666
-2% -$87.8K
2019 Q3
14 quarters
OVID icon
17
Ovid Therapeutics
OVID
$473M
$2.23M 0.59%
864,822
– –
2019 Q3
14 quarters
KZR icon
18
DELISTED
Kezar Life Sciences
KZR
$2.16M 0.57%
68,945
-120,000
-64% -$6.94M
2019 Q3
14 quarters
FRLN
19
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$2.15M 0.57%
315,295
-5,666
-2% -$44K
2020 Q3
10 quarters
CRVS icon
20
Corvus Pharmaceuticals
CRVS
$849M
$2.13M 0.57%
2,339,402
-45,000
-2% -$35.1K
2019 Q3
14 quarters
SYRS icon
21
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.05M 0.54%
+767,445
New +$2.98M
2023 Q1
0 quarters
TRDA icon
22
Entrada Therapeutics
TRDA
$215M
$817K 0.22%
+56,374
New +$753K
2023 Q1
0 quarters
ONCR
23
DELISTED
Oncorus, Inc.
ONCR
$815K 0.22%
2,367,436
– –
2020 Q4
9 quarters
RXDX
24
CALL
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$108K 0.03%
+25,000
New +$2.88M
2023 Q1
0 quarters
LABD icon
25
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$134M
– –
-2,500
Closed -$431K –
1
2

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q1 2023 Portfolio in Review

As of Q1 2023, CHI Advisors held 27 positions worth $377M, up 0.33% from $375M the previous quarter. Its ten largest holdings account for 90% of the portfolio.

CHI Advisors's Q1 2023 filing shows 4 new, 7 increased, 9 reduced and 3 closed positions. Its largest new stake was Chinook Therapeutics, Inc. Common Stock: 135,000 shares worth $3.13M. The largest sale was Kezar Life Sciences, an estimated $6.94M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

  • CHI Advisors's largest Q1 2023 buy was Chinook Therapeutics, Inc. Common Stock: 135,000 shares worth $3.13M.
  • CHI Advisors added most to 2seventy bio in Q1 2023, an estimated $5.97M increase.
  • CHI Advisors's biggest Q1 2023 reduction was Kezar Life Sciences, cutting an estimated $6.94M.
  • CHI Advisors fully exited G1 Therapeutics, Inc. Common Stock in Q1 2023, selling an estimated $1.81M.
  • CHI Advisors's ten largest holdings make up 90% of its $377M portfolio in Q1 2023.
  • CHI Advisors opened 4 new positions and closed 3 in Q1 2023.
  • CHI Advisors's portfolio value rose 0.33% quarter-over-quarter to $377M.

Based on CHI Advisors's 13F filing for Q1 2023, filed 11 May 2023.